High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study

Journal of the Neurological Sciences
Pierangelo BarberoL Durelli

Abstract

Long-term trials have demonstrated the continued efficacy of interferon (IFN) beta treatment in patients with relapsing-remitting (RR) multiple sclerosis (MS) during prolonged administration. The objective of the work was to evaluate the effects of reducing IFN beta administration frequency and total weekly dose in patients with RR MS who have achieved clinical and MRI disease activity stabilization during long-term IFN beta-1b treatment. Prospective 1-year follow-up of 27 RR MS patients on long-term 250 microg every other day (standard dose) IFN beta-1b treatment were randomized either to gradually reduce dose to 30 microg once-a-week IFN beta-1a (13 patients), or to continue on IFN beta-1b standard dose (14 patients). We found significant differences in the two group of patients. In the group of patients continuously treated with IFN beta-1b standard dose, 79% remained relapse free compared to 23% in the group receiving once-weekly IFN beta-1a (p=0.006). The number of patients without new PD/T2 lesions was higher in the group of patients continuously treated with IFN beta-1b standard dose (77%) compared to the once-weekly IFN beta-1a group (23%) (p=0.04). IFN beta is a long-term treatment for MS. The reduction of IFN beta-1b ...Continue Reading

References

Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Jun 10, 1998·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·G AntonelliF Dianzani
Nov 26, 1999·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·S StürzebecherB Aufdembrinke
Nov 27, 2002·Neurology·H PanitchUNKNOWN University of British Columbia MS/MRI Research Group

❮ Previous
Next ❯

Citations

Sep 20, 2005·Journal of Neurology·Luca Durelli, Marinella Clerico
May 17, 2005·Physical Medicine and Rehabilitation Clinics of North America·Jack S Burks
Feb 24, 2009·Current Medical Research and Opinion·S Mitchell Freedman
Mar 27, 2012·Clinical Therapeutics·Elias ZintzarasGeorgios M Hadjigeorgiou
Mar 23, 2007·Journal of the Neurological Sciences·Marinella ClericoLuca Durelli
Aug 23, 2011·Brain Research·W Tristram ArscottYang Mao-Draayer
Dec 2, 2005·Expert Opinion on Pharmacotherapy·Jordi Río, Xavier Montalban
Jun 20, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ritika JainiVincent K Tuohy
Nov 28, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Barbara TeterBianca Weinstock-Guttman
Apr 9, 2008·Pharmacoepidemiology and Drug Safety·Helen TremlettAnne-Louise Ponsonby
Apr 28, 2005·Expert Review of Neurotherapeutics·Jack Burks
May 14, 2005·Current Opinion in Neurology·Joep Killestein, Chris H Polman
Nov 14, 2019·Journal of Neurology·Luca ProsperiniGiancarlo Di Battista
Apr 4, 2017·Archives of Toxicology·Giorgia PalloccaMarcel Leist

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.